OC-0287 Dose to the dominant intraprostatic lesion using HDR vs. LDR monotherapy: Phase II Randomized trial. (April 2019) - Crook, J.; Batchelar, D.; Hilts, M.; Anderson, D.; Bachand, F.; Tissaverasinghe, S.; Farnquist, B.; Bainbridge, T.; Araujo, C.